COVID-19 outcomes of patients with gynecologic cancer in New York City.
Olivia D LaraRoisin E O'CearbhaillMaria J SmithMegan E SutterAnne KniselyJennifer McEachronLisa R GaborJustin JeeJulia E FehnigerYi-Chun LeeSara S IsaniJason D WrightBhavana PothuriPublished in: Cancer (2020)
The case fatality rate among gynecologic oncology patients with a coronavirus disease 2019 (COVID-19) infection is 14.0%; there is no association between cytotoxic chemotherapy and cancer-directed surgery and COVID-19 severity or death. As such, patients can be counseled regarding the safety of continued anticancer treatments during the pandemic. This is important because the ability to continue cancer therapies for cancer control and cure is critical.
Keyphrases
- coronavirus disease
- papillary thyroid
- sars cov
- squamous cell
- end stage renal disease
- minimally invasive
- type diabetes
- squamous cell carcinoma
- newly diagnosed
- young adults
- respiratory syndrome coronavirus
- prognostic factors
- peritoneal dialysis
- metabolic syndrome
- radiation therapy
- acute coronary syndrome
- locally advanced
- skeletal muscle
- rectal cancer
- glycemic control